David M. Epstein, Ph.D. served as the CEO of Black Diamond Therapeutics, Inc. from January 2020 until September 2023. With a strong background in biotechnology and a Ph.D. in a related field, he brought a solid scientific perspective to the...
David M. Epstein, Ph.D. served as the CEO of Black Diamond Therapeutics, Inc. from January 2020 until September 2023. With a strong background in biotechnology and a Ph.D. in a related field, he brought a solid scientific perspective to the helm of the company. During his tenure, Dr. Epstein oversaw important milestones in drug development, particularly with innovative therapies. After stepping down, he remained a board member, indicating his continued interest in the company's future. Interestingly, his compensation varied over his years as CEO, peaking in 2021 when he earned over $5 million, driven mainly by stock options. His separation agreement included significant severance pay, reflecting his influence and contributions. David's journey through significant fluctuations in compensation and insider trading highlights the ups and downs typical in biotechnology firms, where the stakes are high, and outcomes can be unpredictable. From multiple millions in stock trades to a strategic departure, his career paints a picture of a passionate leader in the fast-paced biotech world.